Compare NIO Inc. (NIO) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs Nuvalent Inc — how do they compare? NIO Inc. trades at $4.82 (market cap $12.55B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: NIO Inc. is the larger of the two by market cap, and Nuvalent Inc is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| NIO | NUVL | |
|---|---|---|
Market Cap | $12.55B | $9.81B |
Sector | Consumer Cyclical | Technology |
52-Week High | $7.89 | $123.96 |
52-Week Low | $4.44 | $72.16 |
Enterprise Value | $11.78B | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $4.79, down 1.84% with bearish technical signals despite strong delivery growth. The company shows improving fundamentals with revenue reaching $87.49B in 2025 and narrowing losses, though it remains unprofitable with negative cash flow. Analyst sentiment is mixed with 54% buy ratings but technical indicators show selling pressure. Recent vehicle deliveries surged 62.9% year-over-year in June 2026, providing optimism for margin improvement.
NIO presents a high-risk opportunity with significant growth potential but persistent profitability challenges. The stock offers exposure to China's EV market expansion but faces execution risks and competitive pressures. While delivery momentum is strong, investors must weigh the company's cash burn against its market position and Goldman Sachs' recent upgrade to buy with $7 target.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
